삼성바이오에피스 보도자료
Samsung Bioepis' Biologics License Application for SB2 Infliximab Biosimilar Accepted by U.S. Food and Drug Administration
05월 24일 10:10
Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s Biologics License Application (BLA) ...
Samsung Bioepis' Flixabi® Infliximab Biosimilar Recommended for Approval in the European Union
04월 04일 09:00
Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opi...
Samsung Bioepis Enters the European Biopharmaceutical Market with Benepali®, the First Fusion Protein Biosimilar Approved by the European Commission
01월 18일 09:20
Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) approval of Benepali® - a biosimilar referencing Enbrel® (etanercept), also known as SB4 - f...
Samsung Bioepis' RENFLEXIS® Infliximab Biosimilar Receives Regulatory Approval in Korea
2015년 12월 07일
Samsung Bioepis Co., Ltd. today announced that Korea’s Ministry of Food and Drug Safety (MFDS) has approved RENFLEXIS® - a biosimilar version of Remicade® (inflixima...
Samsung Bioepis Receives Positive CHMP Opinion for the First Etanercept Biosimilar in the European Union
2015년 11월 23일
Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opi...
삼성바이오에피스
상장여부 : 비상장
본사 소재지 : 인천
업종: 건강-제약
웹사이트: http://www.samsungbioepis.com
기업 개요:
등록된 회사소개가 없습니다.